• NextCell Pharma Q2 net sales more than doubled to SEK 3 million, driven entirely by Cellaviva sales of SEK 3 million.
• Loss after financial items widened to SEK 11.7 million; cash and cash equivalents fell to SEK 21.1 million.
• Operating cash flow deepened to a SEK 11.4 million outflow, while total cash flow swung to a SEK 11.2 million outflow.
• First-half net sales climbed 18.75% to SEK 5.7 million; loss after financial items widened to SEK 22.1 million.
• Launched research-use product NextCell-Cord RUO with FUJIFILM Biosciences; rolled out NXTCL naming across drug candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCell Pharma AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.